What to Watch in Tilray’s Q3 Report After the Close
Tilray is scheduled to release its third-quarter financial results after the markets close on Tuesday and analysts are looking for a net loss.
This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.
Tilray Inc. (NASDAQ: TLRY) is scheduled to release its third-quarter financial results after the markets close on Tuesday. Consensus estimates are calling for a net loss of $0.14 per share on $10.12 million in revenue.
This quarter saw a huge run for the stock, although it has mostly settled down since then. One of the driving forces for this run was an approval by the U.S. Drug Enforcement Agency (DEA) for Tilray to export cannabis to the United States for medical research purposes. A week prior to this, the company received approval to export medical cannabis flower to Germany. Tilray already had gained approval to export cannabis-derived oils to Germany.
Marijuana for legal recreational and adult use became legal last month in Canada, and that could drive Tilray sales higher. The company has struck deals with some Canadian firms to supply marijuana for use in recreational and adult-use products.
The party in marijuana stocks began in August with the announcement that beverage giant Constellation Brands had invested $4.2 billion in Canopy Growth, another Canadian grow company. Other big beverage makers like Molson Coors and, more recently, Coca-Cola reportedly were looking for partners as they weighed creating marijuana-infused drinks.
[nativounit]
Excluding Tuesday’s move, Tilray has vastly outperformed the broader market, with its stock up over 400% since it came public. However, in the past 30 days the stock is down about 23%.
Only a handful of analysts have weighed in on Tilray ahead of the report:
- Benchmark has a Buy rating with a $200 price target.
- Cowen has an Outperform rating and a $172 price target.
- Northland Securities has a Market Perform rating.
- Roth Capital has a Neutral rating.
Shares of Tilray were last seen down fractionally at $113.06, with a post-IPO range of $20.10 to $300.00. The stock has a consensus analyst price target of $147.33.
[recirclink id=504674]
[wallst_email_signup]
Contact [email protected] for any questions or corrections.
Chris Lange is a financial and geopolitical writer with more than a decade of experience covering a myriad of topics. He has published thousands of articles for 24/7 Wall St., with past coverage focused heavily on stocks, IPOs, healthcare, defense, global affairs, and technology.
His work has been quoted, or referenced by a number of outlets including Business Insider, USA Today, Yahoo Finance, MSN, The Motley Fool, and many other publications. A graduate of Southwestern University, he studied business with a focus on investments and has previous experience in banking and startups.
When not reading or writing the news, he is following his passion for Lacrosse, playing chess, or building solar projects with his dad.
